

Priority-driven Collaborative Cancer Research Scheme 2012

Cancer Australia; Australian Rotary Health; Cancer Council Australia; Cancer Council New South Wales; Cure Cancer Australia Foundation; National Breast Cancer Foundation; and Prostate Cancer Foundation of Australia, are pleased to announce applicants who have been recommended for funding in the 2012 Round of the Priority-driven Collaborative Cancer Research Scheme.

Beaumont, Kimberley

Centenary Institute of Cancer Medicine and Cell Biology

The role of Rab27a and Rab5a in melanoma phenotype switching

Funded by Cure Cancer Australia Foundation

Bowden, Nikola

University of Newcastle

Investigation of the nucleotide excision repair pathway for melanoma biomarkers

Funded by Cure Cancer Australia Foundation

Buchanan, Daniel

Queensland Institute of Medical Research

Germline copy number variants are genetic risk factors for familial colorectal cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Butler, Lisa

University of Adelaide

A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer

Co-funded by Prostate Cancer Foundation of Australia and Cancer Australia

Colvin, Emily

Kolling Institute of Medical Research

Investigating the tumour-promoting phenotype of cancer-associated fibroblasts in serous epithelial ovarian cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Friedlander, Michael

The Prince of Wales Hospital

ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer

Co-funded by Cancer Council Australia and Cancer Australia— gynaecological cancers program

Georgy, Smitha

Monash University

The role of mammalian transcription factor Grainyhead-like 3 in oesophageal cancer

Funded by Cure Cancer Australia Foundation

Grimison, Peter

University of Sydney

Accelerating first-line chemotherapy to improve cure rates for advanced germ cell tumours: an Australian-led, international randomised trial

Funded by Cancer Council Australia and Cancer Australia

Hayne, Dickon

University of Western Australia

Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial

Funded by Cancer Australia

Hong, Angela

University of Sydney

Improving the outcomes of oropharyngeal cancer: specific human papillomavirus oncoproteins and p53 mutations as modifying factors

Funded by Cure Cancer Australia Foundation

Hutchinson, Andrew

University of Technology Sydney

Molecular characterisation of a novel target in multiple myeloma

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Janda, Monika

Queensland University of Technology

Mirena ± Weight Loss to treat early Endometrial Cancer: (MAxWEL Trial)

Funded by Cancer Australia– gynaecological cancers program

Jayachandran, Aparna

Ludwig Institute for Cancer Research

Hitting a moving target – overcoming invasion and resistance mechanisms by understanding melanoma plasticity using a combination of pre-clinical models

Funded by Cure Cancer Australia Foundation

Jin, Feng

The Kirby Institute

Testing of biomarkers of human papillomavirus on anal cytology in homosexual men to predict the presence of high-grade anal intraepithelial neoplasia and its progression and persistence

Funded by Cure Cancer Australia Foundation and Cancer Australia

Lucas, Robyn

Australian National University

Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency

Funded by Cancer Australia

Micklethwaite, Kenneth

Westmead Hospital

Production of off the shelf T-cells expressing a non-MHC restricted CD19 specific chimeric antigen receptor for use in a Phase I study of T-cell therapy of relapsed and refractory B cell malignancies (UNI-T Study)

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Mielke, Lisa

Walter and Eliza Hall Institute of Medical Research

Innate immune cell protection and colon cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Morton, Rachael

University of Sydney

The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation

Funded by Cancer Australia

Moujalled, Donia

Walter and Eliza Hall Institute of Medical Research

Mechanisms of RIPK3 activation by TNFR1

Funded by Cure Cancer Australia Foundation

Nunez da Costa, Patricia

Austin Hospital

The role of kinin receptors in liver regeneration and growth of colorectal liver metastases

Funded by Cure Cancer Australia Foundation

O'Reilly, Lorraine

Walter and Eliza Hall Institute of Medical Research

Understanding the role of NF- κ B in the progression of gastric adenocarcinomas and assessment of new therapies

Funded by Cancer Council NSW

Pangon, Laurent

Garvan Institute of Medical Research

Characterising a new mode of regulation of the beta-catenin pathway in colorectal cancer

Funded by Cure Cancer Australia Foundation and Cancer Australia

Payne, Richard

University of Sydney

Preparation and evaluation of synthetic self-adjuvanting cancer vaccine candidates

Funded by Cure Cancer Australia Foundation

Pearson, Sallie

University of Sydney

The use and impact of high cost targeted cancer medicines: theory and reality

Co-funded by National Breast Cancer Foundation and Cancer Australia

Perrow, Kara

University of Wollongong

Development of bifunctional anti-uPA/Anti-HER-2 lipidic nanoparticles to target advanced breast cancer

Funded by Cure Cancer Australia Foundation

Price, Timothy

The Queen Elizabeth Hospital

PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer

Funded by Cancer Australia

Pritchard, Antonia

Queensland Institute of Medical Research

Identification of novel tumour epitopes as targets for immunotherapy

Funded by Cure Cancer Australia Foundation

Risbridger, Gail

Monash University

Defining epigenetic changes in prostate cancer stroma

Funded by Cancer Australia

Salmon, Jessica

Peter MacCallum Cancer Centre

Epigenetic therapies for the treatment of acute myeloid leukaemia

Funded by Cure Cancer Australia Foundation

Schofield, Penny

Peter MacCallum Cancer Centre

Solving Unknown Primary cancer – SUPER

Funded by Cancer Australia

Southey, Melissa

University of Melbourne

High risk genes for lobular breast cancer

Co-funded by National Breast Cancer Foundation and Cancer Australia

Tilley, Wayne

University of Adelaide

Mechanism and targeting of castration-resistant prostate cancer

Co-funded by Australian Rotary Health, Prostate Cancer Foundation of Australia and Cancer Australia

Tilley, Wayne

University of Adelaide

Targeting the androgen receptor in triple negative breast cancer

Co-funded by National Breast Cancer Foundation and Cancer Australia

Tomlinson, Christopher

Children's Medical Research Institute

Investigating the mechanism of action of the cancer-associated enzyme telomerase using disease linked telomerase mutants

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Ugalde, Anna

St Vincent's Hospital

The role and contribution of Australia's cancer caregivers

Funded by Cure Cancer Australia Foundation

Waithman, Jason

Telethon Institute for Child Health Research

Induction of adaptive immunity during melanoma

Funded by Cure Cancer Australia Foundation

Weigmans, Adrian

Queensland Institute of Medical Research

RAD51 overexpression regulates pro-metastatic gene expression profiles of aggressive metastatic triple negative breast cancer

Co-funded by Cure Cancer Australia Foundation and Cancer Australia

Zheng, Yu

ANZAC Research Institute

Mechanisms of self-amplification and tumour growth in breast and prostate cancer metastases to bone

Funded by Cure Cancer Australia Foundation